A neuromuscular drug candidate acquired through Novartis’s (NVS) $12 billion Avidity Biosciences deal missed its late-stage primary endpoint, compounding a difficult stretch for the Swiss drugmaker’s pipeline. The setback raises fresh questions about the return on...